Want to see DE:FRE5EN full AI Analyst Report?
FRE5EN Stock Chart & Stats
€43.80
€0.45(1.03%)
At close: 4:00 PM EDT
€43.80
€0.45(1.03%)
Day’s Range― - ―
52-Week Range€35.11 - €52.96
Previous CloseN/A
VolumeN/A
Average Volume (3M)750.62K
Market Cap
€26.10B
Enterprise Value€33.35K
Total Cash (Recent Filing)€1.28B
Total Debt (Recent Filing)€11.42B
Price to Earnings (P/E)17.3
Beta0.86
Next Earnings
Nov 04, 2026EPS Estimate
0.78Next Dividend Ex-DateN/A
Dividend Yield2.24%
Share Statistics
EPS (TTM)2.75
Shares Outstanding563,237,300
10 Day Avg. Volume787,875
30 Day Avg. Volume750,621
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.44
Price to Sales (P/S)1.21
P/FCF Ratio23.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€55.28Price Target Upside26.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)3.6
Revenue Forecast (FY)€23.72B
Bulls Say, Bears Say
Bulls Say
Recurring, Sticky RevenueFresenius’s core dialysis and hospital services generate recurring, payer-reimbursed treatment fees and repeat product sales. This creates predictable cash flows and patient stickiness, sustaining revenue visibility over months and supporting long-term service scale and cross-selling of products to care sites.
Margin Recovery And Operating ProfitabilityOperating margins have materially improved from the 2023 trough, reflecting restored profitability and operating leverage across care delivery and product divisions. Sustained mid-teens EBITDA and double-digit operating margins enhance internal funding capacity and resilience to sector cost pressures over the medium term.
Stronger Balance Sheet / DeleveragingMaterial reduction in leverage meaningfully lowers financial risk and increases strategic flexibility. A cleaner balance sheet improves capacity for targeted capital allocation, acquisitions or capex, and reduces refinancing strain, strengthening the company’s ability to invest through industry cycles.
Bears Say
Weakening Free Cash FlowAlthough FCF is positive, the decline and weak cash conversion versus net income reduce internal funding flexibility. Persistently lower FCF limits capacity for debt reduction, reinvestment or dividend growth and raises sensitivity to working capital swings or higher capex requirements over the medium term.
Uneven Revenue TrajectoryRevenue has recovered from a weak base, but the uneven multi-year trajectory signals potential demand or reimbursement variability across segments. Inconsistent top-line growth complicates capacity planning and could constrain sustainable margin expansion absent more durable organic growth drivers.
Moderate Returns Vs Prior PeaksRebound in ROE is positive but still below historical highs, indicating returns and asset efficiency have not fully normalized. Moderate returns can limit excess capital for shareholders and suggest further operational improvement is needed to reach prior profitability and justify sustained higher reinvestment.
FRE5EN FAQ
What was Fresenius SE & Co. KGaA’s price range in the past 12 months?
Fresenius SE & Co. KGaA lowest stock price was €35.11 and its highest was €52.96 in the past 12 months.
What is Fresenius SE & Co. KGaA’s market cap?
Fresenius SE & Co. KGaA’s market cap is €26.10B.
When is Fresenius SE & Co. KGaA’s upcoming earnings report date?
Fresenius SE & Co. KGaA’s upcoming earnings report date is Nov 04, 2026 which is in 81 days.
How were Fresenius SE & Co. KGaA’s earnings last quarter?
Currently, no data Available
Is Fresenius SE & Co. KGaA overvalued?
According to Wall Street analysts Fresenius SE & Co. KGaA’s price is currently Undervalued.
Does Fresenius SE & Co. KGaA pay dividends?
Fresenius SE & Co. KGaA pays a Annually dividend of €1.05 which represents an annual dividend yield of 2.24%. See more information on Fresenius SE & Co. KGaA dividends here
What is Fresenius SE & Co. KGaA’s EPS estimate?
Fresenius SE & Co. KGaA’s EPS estimate is 0.78.
How many shares outstanding does Fresenius SE & Co. KGaA have?
Fresenius SE & Co. KGaA has 563,237,300 shares outstanding.
What happened to Fresenius SE & Co. KGaA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Fresenius SE & Co. KGaA?
Currently, no hedge funds are holding shares in DE:FRE5EN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fresenius SE & Co. KGaA Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€55.28 (26.22% Upside)
€55.28 (26.22% Upside)
Insider Transactions
Bought Shares
Worth €197.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
50.67%
12-Months-Change
Fundamentals
Return on Equity
2.24%
Trailing 12-Months
Asset Growth
1.27%
Trailing 12-Months
Company Description
Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA operates as a diverse healthcare enterprise, supplying a comprehensive array of products and services primarily focused on dialysis, hospital management, and outpatient medical care. Its activities are structured across four main divisions: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care division is dedicated to individuals living with chronic kidney failure, offering essential items like dialyzers, hemodialysis machines, and related disposable supplies, alongside various dialysis-specific services. Fresenius Kabi concentrates on the therapeutic treatment and care of ill patients. Its extensive product range includes intravenous pharmaceuticals, such as generic drugs for oncology, anesthetics, pain relief, anti-infectives, and critical care. Additionally, it provides parenteral and enteral nutritional products, infusion solutions, and blood volume expanders for infusion therapy. The segment also develops biosimilars—biological medicines for autoimmune and cancer conditions—and manufactures medical devices and disposables crucial for administering IV generics, infusion treatments, and clinical nutrition. Transfusion products for blood component collection and corporeal therapies are also part of its offerings. Fresenius Helios manages significant healthcare operations, encompassing 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers throughout Germany. In Spain, its presence includes 49 hospitals, 88 outpatient clinics, and around 300 risk prevention centers. This segment also delivers fertility treatment services through 33 clinics and an additional 39 sites located across 10 countries on three continents. Finally, the Fresenius Vamed division specializes in project management and service delivery for hospitals and other healthcare facilities. Its offerings span project development, meticulous planning, and turnkey construction solutions. Furthermore, it provides ongoing maintenance, technical oversight, and operational management services. The company, initially known as Fresenius SE, officially changed its name to Fresenius SE & Co. KGaA in January 2011. Founded in 1912, Fresenius SE & Co. KGaA maintains its corporate headquarters in Bad Homburg vor der Höhe, Germany.
FRE5EN Stock 12 Month Forecast
Average Price Target
€55.28
▲(26.22% Upside)
Technical Analysis
CompuGroup Medical
―
Draegerwerk AG & Co. KGaA
―
Fresenius Medical Care AG & Co. KGaA
―
MEDICLIN
―
RHON-KLINIKUM AG
―